Eli Lilly and Co., which transformed itself from a stodgy underperformer into one of the world’s hottest pharmaceutical companies, said this week that the genetic medicine research center it plans to open in Boston in August will eventually employ twice as many workers as originally estimated.
In February 2022, Lilly said that it would increase its modest Massachusetts workforce from 120 to 250 employees when it opened the $700 million Lilly Institute for Genetic Medicine along Fort Point Channel. The Indianapolis-based company said it would move 120 scientists from Kendall Square in Cambridge to the institute and add another 130.
But Daniel Skovronsky, Lilly’s chief scientific and medical officer, said in an interview that the 12-story, 334,000-square-foot laboratory and office building will ultimately accommodate 500 Lilly scientists and researchers.